Skip to main content
SpringerLink
Log in

A Validated, Specific, Stability-Indicating RP-LC Method for Analysis of Gatifloxacin in the Presence of Degradation Products and Process-Related Impurities

  • Full Short Communication
  • Published:
Chromatographia Aims and scope Submit manuscript

Abstract

A validated, specific, stability-indicating reversed-phase liquid chromatographic method has been developed for quantitative analysis of gatifloxacin, its degradation products, and its process-related impurities in bulk samples and in pharmaceutical dosage forms. Forced degradation of gatifloxacin bulk sample was conducted in accordance with ICH guidelines. Acidic, basic, neutral, and oxidative hydrolysis, thermal stress, and photolytic degradation were used to assess the stability-indicating power of the method. Substantial degradation was observed during oxidative hydrolysis. No degradation was observed under the other stress conditions. The method was optimized using samples generated by forced degradation and sample solution spiked with impurities. Good resolution of the analyte peak from peaks corresponding to process-related impurities and degradation products was achieved on a C18 column by use of a simple linear mobile-phase gradient prepared from mixtures of acetonitrile and an aqueous solution of sodium dihydrogen orthophosphate dihydrate and triethylamine adjusted to pH 6.5 with orthophosphoric acid. Detection was performed at 240 nm. Limits of detection and quantification were established for gatifloxacin and its process-related impurities. When the stressed test solutions were assayed by comparison with gatifloxacin working standard the mass balance was always close to 99.3%, indicating the method was stability-indicating. Validation of the method was performed in accordance with ICH requirements. The method was found to be suitable for checking the quality of bulk samples of gatifloxacin at the time of batch release and also during storage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gore J, Bryant Z, Stone MD, Nollmann M, Cozzarelli NR, Bustamante C (2006) Nature 439:100–104. doi:10.1038/nature04319

    Article  CAS  Google Scholar 

  2. Arteseros AH, Barbosa J, Compañó R (2002) J Chromatogr A 945:1–24. doi:10.1016/S0021-9673(01)01505-9

    Article  Google Scholar 

  3. Lorian V (ed) (1996) Antibiotics in laboratory medicine, 4th edn. Williams and Wilkins, Baltimore, pp 591–592

    Google Scholar 

  4. Samanidou VF, Demetriou CE, Papadoyannis IN (2003) Anal Bioanal Chem 375:623–629

    CAS  Google Scholar 

  5. Al-Dgither S, Alvi SN, Hammami MM (2006) J Pharm Biomed Anal 41:251–255. doi:10.1016/j.jpba.2005.09.026

    Article  CAS  Google Scholar 

  6. Kothapalli L, Deshpande AD (2007) Indian J Pharm Sci 69:525–528

    Article  Google Scholar 

  7. Jiang W, Guoa CC, Donga P, Chua ZJ, Wanga L, Jiang W (2008) Luminescence 23:7–13. DOI: 10.1002/bio.1008

    Article  CAS  Google Scholar 

  8. ICH (1994) Text on validation of analytical procedures, Q2A (R1). International Conference on Harmonization, IFPMA, Geneva

  9. US Food and Drug Administration (2001) Guidance for industry: analytical procedures and methods validation: chemistry, manufacturing, and controls documentation. Draft Guidance. US Food and Drug Administration

  10. ICH (1996) Photo stability testing of new drug substances and products. Q1B, International Conference on Harmonization, IFPMA, Geneva

    Google Scholar 

  11. Shabir GA (2003) J Chromatogr A 987:57–66. doi:10.1016/S0021-9673(02)01536-4

    Article  CAS  Google Scholar 

  12. Ribani M, Bottoli CBG, Collins CH, Jardim ISF, Melo LFC (2004) Quim Nova 27:771. doi:10.1590/S0100-40422004000500017

    CAS  Google Scholar 

  13. United States Pharmacopeia (2000) Validation of compendial methods, 24th edn, USP 24, Section 1225. U.S. Pharmacopeia, Rockville, MD, USA

  14. Centre for Drug Evaluation and Research (1994) Validation of chromatographic methods; reviewer guidance, CMC 3, U.S.FDA(CDER), USA

  15. Bakshi M, Singh S (2002) J Pharm Biomed Anal 28:1011–1040. doi:10.1016/S0731-7085(02)00047-X

    Article  CAS  Google Scholar 

  16. ICH (2003) Stability testing of new drug substances and products Q1A (R2). International Conference on Harmonization, IFPMA, Geneva

Download references

Acknowledgments

The authors wish to thank the management of United States Pharmacopeia—India Private Limited group for supporting this work. We would also like to thank colleagues in the Separation Science Division of Analytical Research of United States Pharmacopeia-India Private Limited for their cooperation in carrying out this work.

Author information

Authors and Affiliations

  1. Reference Standard Laboratory, United States Pharmacopeia-India Private Limited, ICICI Knowledge Park, Turkapally, Shameerpet, Hyderabad, 500 078, India

    M. Lalitha Devi

  2. Department of Chemistry, J.N.T.U. College of Engineering, Anantapur, 515002, India

    K. B. Chandrasekhar

Authors
  1. M. Lalitha Devi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. B. Chandrasekhar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Lalitha Devi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lalitha Devi, M., Chandrasekhar, K.B. A Validated, Specific, Stability-Indicating RP-LC Method for Analysis of Gatifloxacin in the Presence of Degradation Products and Process-Related Impurities. Chroma 69, 985–992 (2009). https://doi.org/10.1365/s10337-009-0989-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1365/s10337-009-0989-z

Keywords

Search

Navigation